Search This Blog

Tuesday, February 16, 2021

More parents seek ADHD diagnosis, drugs for kids to manage remote learning

 Susan McLaughlin's 12-year-old daughter, Isabela, was a straight-A student before the pandemic. Isabela, who lives in a suburb of Columbus, Ohio, excelled at science and math and was already getting high school credit for algebra.

But when her school shut down in March and classes shifted to Zoom, Isabela's grades took a nosedive. She signed on for her virtual class from a desk piled high with books, papers and stuffed animals and then spent hours trying to clean her room instead of focusing on schoolwork. She found herself "paralyzed" by assignments, McLaughlin said, but she wouldn't tell the teacher over email that she was struggling, as she would have done in person.

"It was meltdown after meltdown after meltdown," said McLaughlin, 53, a mother of three from Delaware, Ohio, who works in a high school with chronically truant children.

McLaughlin recalls one time in April when Isabela, who was already diagnosed with severe anxiety, was given a language arts assignment and "fell to pieces."

"She was crying and screaming and hyperventilating and started to get some tics, moving her head and flapping her arms. She had never had them before. That's when we started to consider that it might be ADHD."

McLaughlin spent months trying to bring more structure to Isabela's day by writing lists, schedules, timelines and checkboxes. But as someone who was diagnosed with attention deficit hyperactivity disorder herself a decade ago, McLaughlin realized that she was seeing the same behaviors in Isabela. She thought, "I've got to nip this in the bud."

Isabela is being evaluated by a psychiatrist, a process that takes several hours and requires her teachers to fill out questionnaires about her behavior. McLaughlin hopes that with an ADHD diagnosis, Isabela will be able to get a prescription for a stimulant medication — such as Ritalin, Adderall or Vyvanse — to alleviate her symptoms.

"I know it's super controversial sometimes. But I've been medicated for a long time, and I can't function without taking it," McLaughlin said. "If I don't take my medication, I see an immediate difference in my ability to manage complex tasks, clean the house, get up and cook dinner. So I'm hoping it will have the same effect on her."

Image: Susan McLaughlin and Isabela Burgeson
Susan McLaughlin and Isabela Burgeson do schoolwork.Maddie McGarvey

Growing problems

McLaughlin isn't alone in seeking an ADHD assessment for her child during the pandemic. Two dozen children, pediatricians, psychiatrists, psychologists and researchers all described a crisis among children suffering from inattention and tanking school performance.

Data from specialists involved with diagnosing and treating ADHD show just how much parents are struggling to get help: They are flooding an ADHD support line with questions, and ADHD diagnoses and prescriptions for related medications have soared.

"Covid has been a tipping point that has pushed some families to get help," said Dr. Melvin Oatis of the American Academy of Child and Adolescent Psychiatry, who said the stress of the pandemic, the shift to remote learning and social isolation have created "anxiety-provoking" conditions that affect students' attention.

Experts warn that children who appear to have symptoms of ADHD should have thorough evaluations to rule out other conditions or stresses related to the pandemic before they seek medication.

"Our concern is that pediatricians and families be very careful to not simply list the symptoms of ADHD, but to look at the child's history and use differential diagnosis to make sure we have the best possible explanation for the symptoms," said Dr. Arthur Lavin, a Cleveland-based pediatrician who has served on several national committees of the American Academy of Pediatrics.

In the meantime, parents are seeking any help they can find. The number of parents calling a help line set up by CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder), a nonprofit that supports people with ADHD, rose by 62 percent since the pandemic started, the organization said. Traffic to its website last year grew by 77 percent compared to 2019.

"We're getting a lot of calls from caregivers who are working at home alongside their children and starting to see more issues with their behavior than they did before," said April Gower-Getz, CHADD's chief operating officer.

They're certainly trying to get their children evaluated more frequently. The Child Mind Institute, a New York-based nonprofit that helps children with mental health disorders and their families, recorded a 20 percent increase in the number of appointments to discuss medication last year compared to 2019. The "lion's share" of the appointments were to discuss medication for ADHD, said Dr. Harold Koplewicz, the institute's founder.

And more parents are getting their children diagnosed and treated with medication for ADHD.

Athenahealth, a technology company that creates practice management software for health care providers, published research in May, drawing on data from its customers, that showed an increase in patients ages 13 to 17 who received new diagnoses of ADHD. From the week of March 9 to the week of March 30, the proportion of visits by teenagers that involved first-time ADHD diagnoses rose by 67 percent. There was a similar spike among teenagers — particularly boys — who received prescriptions for ADHD medicines for the first time.

The cases also seem to have picked up in recent months, said psychologist Keith Sutton, director of the Bay Area Center for ADD/ADHD. He said he had a "sharp increase" in inquiries during the fall.

"Before the summer, everyone was just trying to get through those months," Sutton said. "Then, in October, when grades were coming back, parents were thinking we're in it for the long run, something is going on here and we need help."

Image: Isabela Burgeson
Isabela Burgeson thrives with in-person schooling but has been struggling during virtual learning.Maddie McGarvey / for NBC News

Why now?

Experts attribute the increase in inquiries to a variety of factors, including the loss of structure and accommodations in the classroom setting.

Parents are also seeing their children's troubles during school hours firsthand. Dr. Devang Patel, a family medicine physician in Illinois who specializes in ADHD, is one of several clinicians who said he is fielding more requests from parents for medication for their children.

"When the problem was in front of the teachers, it wasn't really the parents' concern," Patel said. "But now they are at home trying to make their kid sit still for just half an hour and seeing how difficult that is."

Children also miss the school environment, which helped ameliorate such issues. Dr. Jenny Radesky, a Michigan-based developmental behavioral pediatrician, said she has started prescribing stimulants for children as young as 5 and 6 this year. Their ADHD symptoms were manageable in supportive classrooms with flexible teachers, sensory tools and clear routines. But when those structures went away in March, their symptoms flared up.

"I'm watching kids who used to love school become unenthused and unmotivated," said Radesky, who said she was worried about the long-term impact of virtual learning. "They need the social environment at school to learn how to regulate themselves. Without that, they are really struggling."


Parenting challenges

Sasha Harris-Cronin's 8-year-old son, Z (he chose his own name when he was 6), who is in the third grade, was diagnosed with ADHD in 2019 but didn't start medication until last August.

Before the pandemic, Z's school provided accommodations, like seating him directly in front of the teacher, where he wouldn't be distracted, and making sure he ran around outside during recess.

Harris-Cronin said the shift to Zoom for Z was "awful."

"It was so difficult. There were so many tears," she said. Z missed the structure of school and couldn't focus on Zoom classes. He would take an hour to write four words of a writing assignment. Days would go by when he got "absolutely nothing" done.

When she and Z realized that they were "looking down the barrel of another year like this," they visited a psychiatrist, who prescribed Ritalin and Metadate.

"It was mind-blowing," Harris-Cronin said. "He wrote a poem the first day. It's not a miracle cure. But boy, is it an effective tool."

Finding relief

Jahkim Hendrix, 18, of Atherton, California, suspected that he had ADHD for many years. But he didn't get formally evaluated until late last year, during his senior year of high school. He had been falling behind academically the previous year, and when the schools closed in March, it didn't take long for him to "give up completely."

"The teacher would be speaking and I'd go blank," he said, adding that students objected to putting their cameras on for their teachers, which made them — and him — even less accountable. "I would mute my teacher and go on TikTok and stay there for hours. That's what sustained my attention."

He barely passed his junior year of high school, and his grades slid from Ds to Fs as he started his senior year last fall. He and his mom, who was also diagnosed with ADHD as a child, decided it was time to seek help. It took two months to get an appointment with a psychiatrist, who evaluated him for over five hours in mid-December.

In late January, he was diagnosed with ADHD.

"I cried with relief," he said. "I have always been told I have high potential but low performance, and I didn't know why. Now I have a name to the thing that I'm facing, as well as tools and resources to help me."

Worried doctors

Many experts said parents and clinicians need to be extra cautious about diagnosing ADHD during a pandemic because a child might show more signs that meet the criteria for the disorder. A diagnosis simply needs six or more symptoms listed in the Diagnostic and Statistical Manual of Mental Disorders, the book of mental disorders recognized by the American Psychiatric Association. They include making careless mistakes, struggling to stay focused on tasks, having trouble organizing activities, not following through on instructions, avoiding schoolwork, losing items and being easily distracted.

"The pandemic has substantially disrupted the routines of every family, and that is going to make a good number of children feel like they can't pay attention so well," said Lavin, the Cleveland pediatrician. "ADHD might be one of the explanations, but only one. But the stress of a pandemic may also cause inattention."

Medical experts say someone with ADHD was very likely to show signs before the pandemic began. Both the American Academy of Pediatrics and the American Academy of Child and Adolescent Psychiatry recommend lengthy evaluations that take in children's full developmental histories, surveys parents and teachers and compares symptoms to peers their own ages and genders.

A 15-minute office visit with a pediatrician isn't long enough to rule out other causes of inattention, such as anxiety, depression and problems at home, said Sutton of the Bay Area Center for ADD/ADHD.

Image: Susan McLaughlin and Isabela Burgeson
Susan McLaughlin and her daughter, Isabela Burgeson.Maddie McGarvey / for NBC News

Lengthy dependence

As many schools remain closed, some experts said they were concerned about the long-term impact of remote learning for young people with ADHD, particularly teenagers.

Maggie Sibley, a psychologist and researcher at the University of Washington and Seattle Children's Hospital, has written a research paper, accepted by the Journal of Psychiatric Research, showing that symptoms are worsening and stress levels are skyrocketing among adolescents and young adults with ADHD during the pandemic. That has prompted numerous problems, including social isolation and disengagement from class.

"A person with ADHD typically has fewer friends and less social activities in their calendar," she said. "A lot are getting their only social interactions at school."

Students with ADHD were at particular risk of depression and dropping out of school, the study concluded.

"If you are in a situation where you are experiencing chronic boredom, getting poor grades in school, socially isolated and stuck in a house, it's a recipe for depression," Sibley said. While suicide isn't an inevitable result, "we have to be vigilant down the road, especially since we know from research that when people with ADHD get depressed, they are more likely to make suicidal gestures because of their impulsivity."

Susan McLaughlin will find out whether Isabela has ADHD at a follow-up appointment with the psychiatrist on Tuesday. While they wait, Isabela continues to battle with her assignments, particularly on Thursdays and Fridays, when class is entirely self-directed.

"I just want her to be everything she can be, a happy, well-adjusted 12-year-old — or as well-adjusted as anyone can be at this point."

https://www.nbcnews.com/tech/tech-news/great-attention-deficit-more-parents-seek-adhd-diagnosis-drugs-kids-n1257660

2 variants have merged into heavily mutated coronavirus

 Two variants of the SARS-CoV-2 coronavirus that causes covid-19 have combined their genomes to form a heavily mutated hybrid version of the virus. The “recombination” event was discovered in a virus sample in California, provoking warnings that we may be poised to enter a new phase of the pandemic.

The hybrid virus is the result of recombination of the highly transmissible B.1.1.7 variant discovered in the UK and the B.1.429 variant that originated in California and which may be responsible for a recent wave of cases in Los Angeles because it carries a mutation making it resistant to some antibodies.

The recombinant was discovered by Bette Korber at the Los Alamos National Laboratory in New Mexico, who told a meeting organised by the New York Academy of Sciences on 2 February that she had seen “pretty clear” evidence of it in her database of US viral genomes.

If confirmed, the recombinant would be the first to be detected in this pandemic. In December and January, two research groups independently reported that they hadn’t seen any evidence of recombination, even though it has long been expected as it is common in coronaviruses.

Unlike regular mutation, where changes accumulate one at a time, which is how variants such as B.1.1.7 arose, recombination can bring together multiple mutations in one go. Most of the time, these don’t confer any advantage to the virus, but occasionally they do.

Recombination can be of major evolutionary importance, according to François Balloux at University College London. It is considered by many to be how SARS-CoV-2 originated.

Recombination could lead to the emergence of new and even more dangerous variants, although it isn’t yet clear how much of a threat this first recombination event might pose.

Korber has only seen a single recombinant genome among thousands of sequences and it isn’t clear whether the virus is being transmitted from person to person or is just a one-off.


Recombination commonly occurs in coronaviruses because the enzyme that replicates their genome is prone to slipping off the RNA strand it is copying and then rejoining where it left off. If a host cell contains two different coronavirus genomes, the enzyme can repeatedly jump from one to the other, combining different elements of each genome to create a hybrid virus.

The recent emergence of multiple variants of the new coronavirus may have created the raw material for recombination because people can be infected with two different variants at once.

“We may be getting to the point when this is happening at appreciable rates,” says Sergei Pond at Temple University in Pennsylvania, who keeps an eye out for recombinants by comparing thousands of genome sequences uploaded to databases. He says there is still no evidence of widespread recombination, but that “coronaviruses all recombine, so it’s a question of when, not if”.

The implications of the finding aren’t yet clear because very little is known about the recombinant’s biology. However, it does carry a mutation from B.1.1.7, called Δ69/70, which makes the UK virus more transmissible, and another from B.1.429, called L452R, which can confer resistance to antibodies.

“This kind of event could allow the virus to have coupled a more infectious virus with a more resistant virus,” Korber said at the New York meeting.

Lucy van Dorp at University College London says that she hadn’t yet heard about the recombinant, but “would not be overly surprised if some cases start to be detected”.



https://www.newscientist.com/article/2268014-exclusive-two-variants-have-merged-into-heavily-mutated-coronavirus/

Johnson & Johnson files for EU vaccine approval

 US pharmaceutical giant Johnson & Johnson has applied for authorisation for its coronavirus vaccine in the EU with a decision possible by the middle of March, Europe's drugs regulator said Tuesday.

The single-shot vaccine would be the fourth jab to be approved for use across the 27-nation European Union if it gets the green light from the Amsterdam-based European Medicines Agency.

"EMA has received an application for conditional marketing authorisation for a COVID-19 vaccine developed by Janssen-Cilag International", J&J's European subsidiary, the watchdog said.

The regulator "could issue an opinion by the middle of March 2021, provided the company's data on the vaccine's efficacy, safety and quality are sufficiently comprehensive and robust."

With delays to deliveries of three already-authorised vaccines by AstraZeneca, Pfizer/BioNTech and Moderna, the EMA is under pressure from European capitals to speed more into service.

European Commission chief Ursula von der Leyen hailed the news and said Brussels "will be ready to grant authorisation as soon as EMA delivers a positive scientific opinion."

"More safe and effective vaccines are on their way," she added.

J&J's vaccine has been under a "rolling review" by the EMA since December 1.

Two other vaccines are under rolling review with the EMA: by German firm CureVac and US biotech firm Novavax.

The European Commission has ordered 200 million doses of the Johnson & Johnson vaccine with an option for 200 million more. It says 100 million doses should be delivered by June if it is approved.

Johnson & Johnson has asked US regulators for emergency authorisation for the United States.

The vaccine offers logistical advantages because it does not require two doses and the deep-freeze storage needed for some already-approved shots.

J&J announced in late January that clinical trials showed the vaccine was overall 66 percent effective and 85 percent effective in preventing severe forms of the disease.

But it did not protect as well against a highly transmissible virus variant first identified in South Africa, which is spreading rapidly around the world

The J&J shot uses a common-cold causing adenovirus, modified so it cannot replicate, as a "vector" to shuttle genetic instructions into human cells, telling them to create a protein of the coronavirus.

This trains the immune system to be ready for the live coronavirus.

https://medicalxpress.com/news/2021-02-johnson-eu-vaccine.html

Guardant launches surveillance blood test for colorectal cancer recurrence

 Guardant Health has launched a simple blood test to monitor patients after undergoing surgery for colorectal cancer to spot any early signs that tumor cells remain or to catch the disease before it returns.

The Guardant Reveal test, expected to turn around results in one week, is the company’s first liquid biopsy to help manage the treatment of early-stage cancer, and the company plans to make it available for other cancer types in the future.

“For the more than 1.5 million colorectal cancer survivors today in the U.S., the risk of recurrence is a serious one,” Guardant CEO Helmy Eltoukhy said

“Colorectal cancer is the second leading cause of cancer death in the U.S. and an estimated 10% to 30% of early-stage patients recur—so it’s vital that oncologists have better tools to manage these patients by quickly identifying those high-risk patients who may benefit from adjuvant therapy after surgery, and by detecting recurrence earlier as part of regular surveillance,” Eltoukhy said.

The test sifts for fragments of tumor DNA floating in the bloodstream and can help detect recurring cancers months earlier than the current standard imaging procedures and blood tests for carcinoembryonic antigen levels, according to Guardant.

By sequencing and matching the DNA found to the tumor, and by evaluating the genetic material’s larger structure for the telltale signs of cancer, the Guardant Reveal test can deliver a sensitivity of 91%, the company said.

The diagnostic also allows patients to be screened multiple times in the months following surgery, compared to an invasive tissue removal and biopsy procedure.


Last month, in a separate study of the company’s Guardant360 liquid biopsy test for profiling patients with advanced non-small cell lung cancer, a head-to-head analysis found it could detect more genetic mutations than tissue biopsies could.

The findings, published in the ASCO journal JCO Precision Oncology, support the company’s goals of delivering a “blood-first approach” for oncologists and getting more cancer patients access to genetic information about their tumors.

https://www.fiercebiotech.com/medtech/guardant-health-launches-surveillance-blood-test-for-detecting-colorectal-cancer-recurrence

Hospitals Must Now Disclose Prices: Here's How to Interpret Them

 Need a knee replacement and wondering what your out-of-pocket cost might be? Under a new regulation from former President Donald Trump and just enacted by the Centers for Medicare & Medicaid Services (CMS) in January, hospitals must now tell you, as well as prices for other "shoppable" services that can be scheduled, from psychotherapy to routine blood tests.

Kind of.

The rule requires nearly all of the nation's 6,000 hospitals post detailed price breakdowns on their websites for at least 300 services, 70 of which are dictated by CMS. The rest are left up to the hospitals' discretion.

But, as with so much of health care, the reality of hospital price transparency is complicated.

Hospitals must post five prices for each of the procedures: gross charges; discounted cash prices; the charges they've negotiated with insurers and the minimum and maximum negotiated prices. Any hospital that doesn't comply could face penalties of up to $300 a day.

Reasoning Behind Hospital Prices Rule

The government developed the regulation in the hopes of empowering patients to make smarter health care purchases, while encouraging competition among hospitals and insurers that could ultimately push down health costs. But some experts question whether either goal will be met.

"Out-of-pocket estimate tools can be helpful for patients, but even the savviest consumers will struggle to navigate the big data dump required by the rule," says Ariel Levin, senior associate director for policy at the American Hospital Association (AHA).

That group sued the U.S. Department of Health and Human Services, trying to block the rule by claiming it would encourage health insurers' anti-competitive behavior, potentially hindering efforts to control costs. The AHA lost in federal court.

According to a Wall Street Journal article, some of the biggest national and regional hospital systems (including Mayo Clinic, HCA Healthcare and NewYork Presbyterian) have yet to fully reveal their prices.

Complicating the problem for consumers is that interpreting pricing information from hospitals isn't always straightforward.

For example, if a patient insured by Horizon Blue Cross and Blue Shield goes to the website for Hackensack Meridien Health in New Jersey, clicks on its price estimator tool and searches the cost of a knee replacement at that city's main hospital, she may find an out-of-pocket cost estimate of zero.

That would seem like good news, until she scrolls down the page and finds that the hospital's fees for patients without insurance would range from $38,871 to $60,271.

Then there's a disclaimer saying that people with insurance might have to pay some portion of that cash cost in the form of co-pays, co-insurance or deductibles, which are not automatically factored into the estimate.

What's more, the estimate excludes fees charged by the surgeon, who more than likely doesn't work directly for the hospital and therefore would charge separately for the knee replacement. (The regulation was written specifically to cover hospitals.)

How to Find the Prices

So how can you make sense of whatever pricing information hospitals do provide?

The first challenge is finding it.

Although the regulation requires hospitals to post pricing information on their websites, some are burying it, says Dr. Joel Shalowitz, adjunct professor of health industry management at Northwestern University in Chicago. He suggests Googling the name of the hospital and the words "price transparency" to get directly to the page with the information.

The next challenge: dealing with wide discrepancies in the procedures for which prices are offered.

The 70 required by CMS fall into four categories: evaluation and management; laboratory and pathology; radiology and medicine and surgery. The last of those categories includes a broad range of procedures that must be posted, including cataract surgery, electrocardiogram and gallbladder removal. But it's by no means a comprehensive list.

And hospitals can take liberties in deciding which services beyond the required 70 to include in their price disclosures.

Shalowitz sees even more shortcomings with the coming flood of pricing information."What's not included is any mention of quality," he says.

Add to that the reality that many health care services are ordered, and performed, by physicians who often require their patients go to specific hospitals. In that case, "your ability to make a decision based solely on prices doesn't really exist," Shalowitz says.

The bottom line: don't take the price transparency information provided by hospitals at face value.

Who to Ask for Help Getting Information

To ensure you're getting the most accurate cost, call the hospital, the physician who'll be performing the procedure and your health insurer to confirm any information gleaned from price-transparency tools.

"The hospital won't make it easy, but don't give up. Stick to your guns and say 'I want the real prices,'" advises Marni Jameson Carey, executive director of the Association of Independent Doctors.

The task of determining the cost of shoppable health services may get easier in a few years, Carey adds, thanks to a regulation set to roll out starting in January 2022. It will require health insurers to disclose a slew of pricing information online, including in-network negotiated rates, historical net prices for prescription drugs and rates paid for out-of-network doctors.

Some companies plan to take the new price-transparency data and make it easier for consumers to use. They include Healthcare Bluebook, which provides price-comparison apps for employers and other health plan sponsors. The apps let patients compare prices charged by hospitals and independent health providers such as physicians and imaging centers.

Bill Kampine, co-founder of Healthcare Bluebook, expects the data hospitals will be disclosing will enhance his company's apps. "The more data the better — it will help us round out a more complete picture" of health care costs, he says.

So, will all of this transparency ultimately bring down health costs? Don't count on it, says Dr. David Blumenthal, president of the health care research organization Commonwealth Fund.

"Shoppable services are a small fraction of total spending," he says. "This may cause the suppliers of those services to look a little more carefully at their cost structure. But does that cause the entire health system to improve? I don't see that."

https://www.nextavenue.org/hospitals-must-now-disclose-prices-heres-how-to-interpret-them/

Mexico says local AstraZeneca vaccine lab almost rebuilt to meet standards

 The packaging and distribution of AstraZeneca’s COVID-19 vaccine in Mexico had been held up due to a complex certification process that led to major changes at a factory, Mexico’s foreign minister said on Tuesday.

Mexico had not finished producing doses of the vaccine from the shipments of active ingredient that already arrived to the country because its health regulator had to first inspect a local lab and certify that the batches were pure and without defects, Foreign Minister Marcelo Ebrard said.

He said COFEPRIS, the regulator, had made 185 “observations” during a visit to local manufacturer Laboratorios Liomont, which previously made flu jabs and is expected to start shipping the doses by early April.

“They almost had to make another factory,” Ebrard, speaking at a regular government news conference, said about Liomont. “You are talking about health, life ... so you do have to be very strict in any medicine, with a vaccine more, and even more when the vaccine is so recent.”

In partnership with the Mexican and Argentinean governments, AstraZeneca plans to produce millions of doses of the vaccine, developed with Oxford University, for distribution throughout the region. The plan has significant funding from the foundation of Mexican billionaire Carlos Slim.

Liomont and a spokesperson for Mexico’s health ministry did not immediately respond to requests for comment.

Mexico has received at least two shipments of the vaccine’s active ingredient, which were to be packaged locally for about seven million doses that are not yet ready, according to government data.

Looking to speed up its vaccine campaign, which is now focused on older adults, Mexico also imported on Sunday the first 870,000 doses of a planned two million doses of AstraZeneca’s vaccine from India.

Shipments of the Pfizer-BioNTech vaccine also restarted after global delays, with a flight landing on Tuesday in Monterrey and another due later in capital Mexico City. The government said Tuesday’s shipments would provide about 494,000 doses.

Argentina’s President Alberto Fernandez would visit Liomont’s plant during an upcoming trip to Mexico, Ebrard said.

https://www.reuters.com/article/us-health-coronavirus-mexico-astrazeneca/mexico-says-local-astrazeneca-vaccine-lab-almost-rebuilt-to-meet-standards-idUSKBN2AG2DP

White House says will send 13.5M vaccine doses a week to U.S. states

 The White House said on Tuesday it is increasing the supply of coronavirus vaccines sent each week to states to 13.5 million doses, and is also doubling the amount shipped to pharmacies to 2 million doses this week.

White House Press Secretary Jen Psaki said the boost in distribution to states marked a 57% increase since President Joe Biden was inaugurated on Jan. 20.

With a brutal winter storm hitting Texas, causing massive power outages and freezing almost all activity in the state, the White House is working to keep vaccine distribution going there, Psaki said.

“It’s something we’re very mindful of and we contingency plan to ensure people are getting the doses they need at an appropriate timeline,” Psaki said.

https://www.reuters.com/article/us-health-coronavirus-usa-supply/white-house-says-it-will-send-13-5-million-vaccine-doses-a-week-to-u-s-states-idUSKBN2AG28U